The Dark Side of Weight Loss Drugs: An Endocrinologist Explains the Potential Risks and Benefits of Ozempic, Mounjaro, and wegovy

While Ozempic has dominated the weight loss space, Wegovy and Mounjaro are other injectable prescription weight loss drugs worth knowing about. But can these weight loss injections actually help people lose weight and keep it off? What about the health risks and side-effects? While these medications can serve a very critically important purpose for some people, they also come with certain risks.

In an interview with HT Lifestyle, endocrinologist, Dr Saptarshi Bhattacharya, senior consultant, Indraprastha Apollo Hospitals, Delhi and secretary, Endocrine Society of Delhi, said that for some people, these anti-obesity injections, hailed as groundbreaking solutions, seem like a beacon of hope.

“Yet even as their popularity surges, a shadow of controversy looms. In the US, the manufacturers are facing legal trouble, with lawsuits claiming that they downplayed the risks of serious side effects associated with these products. These challenges make us pause and question the safety of these seemingly miraculous injections,” he said.

According to Dr Bhattacharya, while the manufacturing companies maintain that they did nothing wrong, scrutiny is increasing, urging everyone to reexamine the safety of these treatments: “Against this backdrop, it becomes critically important to turn to medical evidence rather than headlines.”

Are anti-obesity injections really effective?

Dr Bhattacharya said, “The medical literature clearly demonstrates the efficacy of anti-obesity injections, such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro), marking a new era in weight management. Clinical trials have demonstrated that these medications can lead to significant and sustained weight loss.”

He elaborated: “For instance, studies on semaglutide have reported an average weight loss of 17 percent over 68 weeks, with one-third of participants shedding 20 percent of their body weight. To put this into viewpoint, a person weighing 100 kg could expect to lose 17 kg on average, and in one-third cases, more than 20 kg.”

He added, “Tirzepatide has shown comparable, and in certain specific cases, even greater efficacy in terms of weight loss.On average, participants lost about 15-20 percent of their body weight, a scale of reduction once thought possible only after bariatric surgery. Remarkably, about half of those on the 10 mg dose and nearly 60 percent on the 15 mg dose lost more than 20 percent of their body weight. In contrast,just 3 percent of people on placebo,who were receiving dietary and exercise advice,achieved that milestone. These numbers explain the global buzz around these medicines.”

According to Dr Bhattacharya, these medications bring about cardiac and metabolic benefits beyond just shedding kilos. “They improve blood glucose, blood pressure, and lipid profiles and reduce systemic inflammation. Notably, semaglutide minimises the risk of major adverse cardiovascular events in individuals with heart disease. Research also points to improvements in conditions linked to obesity, such as obstructive sleep apnea and metabolic dysfunction-associated steatotic liver disease, commonly known as fatty liver, further reinforcing the wide-ranging health benefits of these drugs.”

“`html

Semaglutide and tirzepatide: FDA Warning on Gastrointestinal Issues

The Food and Drug Administration (FDA) has issued a warning to be included on the labels of semaglutide medications regarding a potential risk of gastrointestinal ileus, a condition where the intestines become blocked.This update follows reports received after the drugs were made available to the public, known as post-marketing surveillance. While the exact cause is still under inquiry, both semaglutide and tirzepatide are known to affect the digestive system.

Understanding Semaglutide and Tirzepatide

Semaglutide and tirzepatide are medications primarily used for the treatment of type 2 diabetes and, in some cases, for weight management. They belong to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications work by mimicking the effects of GLP-1, a natural hormone that helps regulate blood sugar levels and appetite. A key mechanism of action for both drugs is slowing down gastric emptying – the rate at which food leaves the stomach – and altering bowel motility.

What is Gastrointestinal Ileus?

Gastrointestinal ileus, often referred to as paralytic ileus, is a temporary condition where the normal muscle contractions that move food through the intestines stop.This can lead to a buildup of food and fluids, causing symptoms like bloating, nausea, vomiting, and abdominal pain.In severe cases, it can lead to bowel obstruction. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides detailed information on ileus.

FDA Findings and Semaglutide

While initial concerns arose from post-marketing reports, a closer examination revealed that semaglutide itself wasn’t definitively linked to a considerably increased risk of bowel obstruction or ileus. However,due to the drugS known affect on slowing gastric emptying,the FDA persistent a label warning was prudent. The FDA’s website is the primary source for official drug safety communications.

Tirzepatide and Gastrointestinal Effects

Tirzepatide, like semaglutide, is associated with common digestive side effects. While specific rates for paralytic ileus are less clearly defined, individual cases of partial small bowel obstruction have been reported.Patients taking tirzepatide should be aware of potential gastrointestinal symptoms and seek medical attention if they experience severe or persistent discomfort. The Mayo Clinic offers patient-pleasant information on tirzepatide.

Symptoms to Watch For

Individuals taking semaglutide or tirzepatide should be vigilant for the following symptoms,and seek immediate medical attention if they occur:

• Severe abdominal pain
• Persistent nausea or vomiting
• Bloating
• Constipation
• Inability to pass gas

Key Takeaways

• The FDA has added a warning about gastrointestinal ileus to the label of semaglutide medications.
• Both semaglutide and tirzepatide can slow gastric emptying and alter bowel motility.
• Semaglutide was not found to significantly increase the risk of bowel obstruction, but the warning was added as a precaution.
• Tirzepatide is associated with common digestive side effects, and individual cases of bowel obstruction have been reported.
• Patients should be aware of potential symptoms and seek medical attention if they experience severe or persistent gastrointestinal issues.

This warning underscores the importance of ongoing monitoring and reporting of side effects associated with these medications. As more data becomes available,the FDA may refine its guidance. Patients should discuss any concerns with their healthcare provider.

Publication Date: 2025/10/02 03:29:02